drugset / Trial / NCT00199342
A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a dose escalating cohort study to determine the maximum tolerated dose (MTD) of KW-2871 (in dose cohorts of 60, 80, and 100 mg/m2) when administered with a specified premedication regimen (ranitidine, diphenhydramine, and dexamethasone). KW-2871 will be administered at 14-day intervals.
Timeline
- Start
- 2004-11
- Primary completion
- 2005-10
- Completion
- —
Outcome
Outcome not reported
Stopped: “Occurrence of 2 dose-limiting toxicities at the initial dose level (60 mg/m2) in Part I.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ECROMEXIMAB | Monoclonal antibody | 60 mg/m2 | Intravenous |
| Subject | ECROMEXIMAB | Monoclonal antibody | 80 mg/m2 | Intravenous |
| Subject | ECROMEXIMAB | Monoclonal antibody | 100 mg/m2 | Intravenous |